

# Continuing Education

## New & Noteworthy Medication Approvals of 2015

### **Authors:**

Kavita Patel  
Pharm.D. Candidate 2016  
Harrison School of Pharmacy, Auburn University

Keith Dasinger  
Pharm.D. Candidate 2016  
Harrison School of Pharmacy, Auburn University

Jeremy Burgess  
Pharm.D. Candidate 2016  
Harrison School of Pharmacy, Auburn University

### **Corresponding Author:**

Bernie R. Olin, Pharm.D.  
Associate Clinical Professor and Director  
Drug Information Center  
Harrison School of Pharmacy, Auburn University

**Universal Activity #: 0178-0000-16-102-H01-P | 1.25 contact hours (.125 CEUs)**

**Initial Release Date: May 5, 2016 | Expires: January 31, 2019**

- For what genetic condition is alirocumab indicated in addition to adjunctive therapy in atherosclerotic cardiovascular disease (ASCVD) patients?
    - Heterozygous familial hypercholesterolemia
    - Homozygous familial hypercholesterolemia
    - Type III hyperlipoproteinemia
    - Type IIb hyperlipoproteinemia
  - How often is subcutaneous alirocumab recommended to be injected?
    - Every week
    - Daily
    - Once monthly
    - Every 2 weeks
  - Which two receptor types does brexpiprazole effect?
    - Norepinephrine and serotonin
    - Dopamine and norepinephrine
    - Serotonin and dopamine
    - GABA and glutamate
  - What is the maximum daily dose of brexpiprazole in schizophrenia and major depressive disorder, respectively?
    - 4 mg and 5 mg
    - 4 mg and 3 mg
    - 5 mg and 3 mg
    - 3 mg and 2 mg
  - Which one of the following statements is false regarding hypoparathyroidism?
    - It may be caused by autoimmune disorders, congenital defects, or by damage with radiation
    - Hypercalcemia is a sign of hypoparathyroidism
    - Hypocalcemia is a sign of hypoparathyroidism
    - Symptoms of hypoparathyroidism include perioral numbness, paresthesia, and carpal/pedal muscle spasms
  - Which medication should not be administered with Natpara®?
    - Alendronate
    - Calcium and vitamin D
    - Phosphorus
    - Brexpiprazole
  - Corlanor® (ivabradine) is FDA indicated for which of the following indications?
    - Heart failure with reduced ejection fraction (HFrEF)
    - Acute decompensated heart failure
    - Hypertension
    - Atrial fibrillation
  - What is the recommended starting dose for Corlanor® (ivabradine) in patients with HR > 60 beats per minute (bpm)?
    - 2.5 mg twice daily
    - 7.5 mg twice daily
    - 5 mg twice daily
    - 5 mg once daily
  - Cosentyx® (secukinumab) is contraindicated with which of the following conditions?
    - Liver impairment
    - Pregnancy
    - Renal impairment
    - Live vaccines
  - Addyi® (flibanserin) is indicated for which of the following populations?
    - Post-menopausal women
    - Premenopausal women
    - Menopausal women
    - Young women
-

11. Which of the following is the black box warning for Addyi® (flibanserin)?
- Combining with cranberry juice
  - Skin atrophy
  - Combining with alcohol
  - Hot flashes
12. What genotype of hepatitis C virus is daclatasvir indicated to treat?
- 1
  - 3
  - 4
  - b and c
13. All of the following are true except...
- After the initial bolus, continuous infusion of cangrelor should be given for the duration of the PCI or 2 hours, whichever is longer
  - Cariprazine is indicated for major depressive disorder (MDD)
  - Daclatasvir should be given with sofosbuvir for 12 weeks
  - Clopidogrel and prasugrel should not be given before cangrelor is discontinued
14. In what percentage of patients has bleeding been observed with cangrelor use?
- 11%
  - 6%
  - 21%
  - 16%
15. Which of the following statements is false?
- Platelet inhibition occurs within 2 minutes of administration of cangrelor
  - Repatha (evolocumab) is indicated for homozygous familial hypercholesterolemia (HoFH)
  - Drug interactions with daclatasvir include CYP 3A4 inducers like St. John's Wort
  - Cangrelor is a member of the Factor Xa inhibitor class

## Participant Information:

AL License # \_\_\_\_\_

Name \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

E-mail \_\_\_\_\_

NABP e-Profile # \_\_\_\_\_

MM/DD (month/day of birth) \_\_\_\_\_

How long did it take you to read the article and complete this test?

\_\_\_\_\_ hours \_\_\_\_\_ minutes

My signature certifies that I have independently taken this CE examination.

\_\_\_\_\_

CE Assessment Answers				
Please circle your answers (one answer per question)				
1.	A	B	C	D
2.	A	B	C	D
3.	A	B	C	D
4.	A	B	C	D
5.	A	B	C	D
6.	A	B	C	D
7.	A	B	C	D
8.	A	B	C	D
9.	A	B	C	D
10.	A	B	C	D
11.	A	B	C	D
12.	A	B	C	D
13.	A	B	C	D
14.	A	B	C	D
15.	A	B	C	D

## Program Evaluation – Must be completed for credit.

Please rate the following items on a scale from 1 (poor) to 4 (excellent).

- |                                   |   |   |   |   |
|-----------------------------------|---|---|---|---|
| 1. Overall quality of the article | 1 | 2 | 3 | 4 |
| 2. Relevance to pharmacy practice | 1 | 2 | 3 | 4 |
| 3. Value of the content           | 1 | 2 | 3 | 4 |

Please answer each question, marking whether you agree or disagree.

4. This course met the learning objectives.  Agree  Disagree
5. The article did not promote a particular product or company.  Yes  No

### Impact of the Activity

The information presented (check all that apply):

6.  Reinforced my current practice/treatment habits  Will improve my practice/patient outcomes  
 Provided new ideas or information I expect to use  Adds to my knowledge
7. Will the information presented cause you to make any changes in how you do your job?  Yes  No
8. How committed are you to making these changes?  
 (Not committed) 1 2 3 4 (Very committed).
9. Do you feel future activities on this subject matter are necessary and/or important?  Yes  No

### Follow-Up

As part of our ongoing quality-improvement effort, we would like to be able to contact you in the event we conduct a follow-up survey to assess the impact of our educational interventions on professional practice. Are you willing to participate in such a survey?

Yes  No



The Alabama Pharmacy Association Research and Education Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.